SAN
FRANCISCO, July 14, 2024 /PRNewswire/ -- AusperBio
Therapeutics, Inc. and Ausper Biopharma Co., Ltd.
(collectively AusperBio), a privately held clinical-stage
biotechnology company dedicated to advancing targeted
oligonucleotide therapies, with the goal of achieving functional
cure for chronic hepatitis B (CHB) infection, today
announced the completion of a $37
million Series A financing round. This round was led by
existing investor, InnoPinnacle Fund, with participation
from new investors including Yuanbio Venture Capital,
Qiming Venture Partners, Hankang Capital, and
Genesis Capital.
AusperBio, Clinical Trail, Chronis
Hepatitis B, AHB-137, Series A Financing, Breakthrough Therapy
Designation (BTD)
The proceeds from the financing will further support the
clinical development of AHB-137, AusperBio's lead product
candidate. Additionally, the funds will advance its proprietary
Med-Oligo™ technology platform and its product
pipelines.
Dr. Guofeng Cheng,
co-founder and CEO of AusperBio, commented: "We
are immensely grateful for the continued support from our
existing investors and are very pleased to welcome new
investors to the company. This financing round represents a
significant milestone that recognizes our scientific and clinical
achievements to date. The shared commitment from our investors to
developing new therapeutics for CHB patients is truly
inspiring. With this funding, together with the recent
Breakthrough Therapy Designation (BTD) from China's CDE, we are well-positioned
to rapidly advance the clinical development of
AHB-137 and move closer to providing a vital new treatment
option for patients with CHB."
About AHB-137
AHB-137, a novel unconjugated antisense oligonucleotide
(ASO) developed within AusperBio's proprietary Med-Oligo™
ASO technology platform, was designed to treat chronic
hepatitis B for a functional cure. Its compelling preclinical and
Phase 1 clinical data was highlighted at the 2023 EASL™
conference and the 2024 EASL™ conference, respectively. This
novel dual-mechanism ASO is presently undergoing a Phase
1b trial across multiple
international study sites and a concurrent Phase 2 trial in
China. Through a
global development strategy, AHB-137 is advancing rapidly
towards the goal of HBV cure.
About AusperBio.
AusperBio is a clinical-stage biopharmaceutical company with
operations in the USA and China, dedicated to advancing oligonucleotide
and targeted delivery technologies for transformative therapies,
with an initial focus on curing chronic hepatitis B infection. The
company has developed a proprietary Med-Oligo™ ASO
platform which has been shown to substantially enhance the current
ASO therapeutics, through novel insights into ASO design. Combining
with efficient targeted delivery conjugation technologies, the
modular Med-Oligo™ Platform empowers ASO therapeutics
to treat a broad range of diseases, including viral infections,
metabolic conditions, genetic disorders, and immune diseases.
For further information, please contact:
Media
Contact
Email: info@ausperbio.com
Investor Relations Contact:
Tel: 650-888-1756 (US)
Email: growth@ausperbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ausperbio-secures-37-million-in-series-a-financing-to-advance-ahb-137-clinical-development-for-hbv-cure-302196465.html
SOURCE AusperBio Therapeutics Inc.